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Acromegaly guidelines updated in 2010 revisited criteria of disease control: if applied, it is likely that a percentage of patients
previously considered as curedmight present postglucoseGHnadir levels not adequately suppressed, with potential implications on
management. This study explored GH secretion, as well as hormonal, clinical, neuroradiological, metabolic, and comorbid profile
in a cohort of 40 acromegalic patients considered cured on the basis of the previous guidelines after a mean follow-up period of
17.2 years from remission, in order to assess the impact of the current criteria. At the last follow-up visit, in the presence of normal
IGF-I concentrations, postglucose GH nadir was over 0.4𝜇g/L in 11 patients (Group A) and below 0.4 𝜇g/L in 29 patients (Group
B); moreover, Group A showed higher basal GH levels than Group B, whereas a significant decline of both GH and postglucose GH
nadir levels during the follow-up was observed in Group B only. No differences in other evaluated parameters were found. These
results seem to suggest that acromegalic patients considered cured on the basis of previous guidelines do not need a more intensive
monitoring than patients who met the current criteria of disease control, supporting instead that the cut-off of 0.4 mcg/L might be
too low for the currently used GH assay.
1. Introduction
The normalization of growth hormone (GH) and insulin-
like growth factor I (IGF-I) secretion is the goal treatment
of acromegaly, since it correlates with reduced mortality and
morbidity risk, as indicated by a large body of epidemiologi-
cal data [1–4]. However, different insidious issues concerning
broad normal ranges, assay performance, and individual
factors, such as age, gender, or BMI, have challenged the
identification of definitive guidelines criteria [5, 6]. In effect,
the definition of normative reference ranges as well as
the criteria for disease remission that best correlate with
morbidity and mortality in acromegaly has been an area of
debate [2, 4, 7].
Indeed, the availability of high purity of the most recent
GH International Standard preparations used for assay cal-
ibration, in conjunction with improved IGF-I International
Standard [8], together with the assessment of the postglucose
GH nadir levels obtained during oral glucose tolerance test
(OGTT) in healthy subjects, has led us to define progressively
more strict cut-off. Accordingly, the Acromegaly Consensus
Group recently revisited the guidelines on criteria for disease
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Table 1: Pre- and postoperative hormonal data of overall acromegalic patients (𝑛 = 40) during longitudinal follow-up; postglucose GH nadir
levels are additionally categorized by sex and tumor size. Mean ± SD values are shown.
Parameter Preoperative Phase 1 Phase 2 Phase 3
Mean (years) — 0.7 ± 0.4 6.9 ± 5.4 17.2 ± 8.4
Age (years) 40.4 ± 12.3 45.1 ± 11.3 50.7 ± 11.0 55.4 ± 11.3
IGF-I (SDS) 9.6 ± 5.2 0.6 ± 1.9 −0.32 ± 0.9 −0.28 ± 1.1◼
Basal GH (𝜇g/L) 19.9 ± 20.4 1.1 ± 0.9 1.0 ± 1.4 0.9 ± 1.2
Range (1.0–73.0) (0.0–3.0) (0.0–7.0) (0.0–4.4)
Nadir GH (𝜇g/L) 16.0 ± 21.9 0.39 ± 0.38 0.27 ± 0.29 0.22 ± 0.20◼
Female (𝑛 = 25) 19.6 ± 27.7 0.45 ± 0.42 0.27 ± 0.25 0.24 ± 0.21◼
Male (𝑛 = 15) 11.2 ± 9.5 0.30 ± 0.30 0.29 ± 0.37 0.21 ± 0.19
Micro (𝑛 = 15) 7.2 ± 6.0 0.27 ± 0.29 0.22 ± 0.27 0.18 ± 0.18
Macro (𝑛 = 25) 27.0 ± 28.5a 0.51 ± 0.42 0.31 ± 0.31 0.25 ± 0.21◼
Phase 1: at the time of remission.
Phase 2: at the time of the last available assessment with the GH assay standardized to IS 80/505.
Phase 3: after a long-term follow-up with ultrasensitive GH assay standardized to IS 98/574.
Micro: microadenoma; macro: macroadenoma.
◼
𝑃 < 0.05 versus phase 1.
a
𝑃 < 0.05 versus microadenoma.
control as defined in Cortina in 2000 and recommended
a regular retesting in patients with normal age-adjusted
IGF-I levels and postglucose GH nadir levels after OGTT
≥ 0.4mcg/L, obtained using assays that contain standards
calibrated against the WHO 2nd International Standard
(IS) 98/574, with antibodies which essentially recognize the
22 kDa isoform andwith results expressed asmass unit (𝜇g/L)
[8–10].
In a previous study carried out on patients defined in
remission based on postglucose GH nadir levels < 1 𝜇g/L
(obtained with GH assays standardized to the previously
adopted IS, i.e., code 80/505) together with normal IGF-I
levels, we did not find any differences in terms of biochemical,
clinical, and neuroradiological recurrence between acrome-
galic patients with postglucose GH nadir levels above and
below an arbitrarily defined tight cut-off of 0.26𝜇g/L, that
is, mean + 2SD of healthy controls, suggesting that lowering
of cut-off postglucose GH nadir values did not improve the
discrimination of long-lasting disease remission [11].
Aim of the study was to reevaluate, after a long-term
follow-up period (mean: 17.2 ± 8.4 years, range: 3–35 yrs.)
and using the latest recommended International Standard for
GH and IGF-I assays, a cohort of acromegalic patients that
we considered cured on the basis of the previous guidelines
to assess disease status according to the new consensus
and, therefore, to compare the clinical characteristics and
comorbidities of the two groups of patients (e.g., patients who
fulfill the current criteria and patients who do not), in order
to define long-term remission.
2. Subjects and Methods
2.1. Patients. The patients recruited for the study were part
of a larger cohort of acromegalic patients who, at the time
of the last assessment available with GH assay standardized
to IS 80/505, were considered cured according to Cortina
Consensus (i.e., normal age-adjusted IGF-I levels and post-
glucose GH nadir < 1 𝜇g/L) [8], after therapy surgery and/or
radiation. Further inclusion criteria used for the selection of
patients were as follows: minimum follow-up of 3 years after
disease remission, complete pre- and postoperative follow-
up status (i.e., clinical, hormonal, and neuroimaging data),
and availability of long-term assessment with GH and IGF-
I assays standardized to WHO IS 98/574 and IS 02/254,
respectively.
Forty acromegalic patients (25 females and 15 males, at
diagnosis mean age ± SD 40.4 ± 12.3 yrs., BMI ± SD 27.0 ±
4.3Kg/m2, serum GH ± SD mean 19.9 ± 20.4 ng/mL, serum
postglucose GH nadir ± SD 16.0 ± 21.9 ng/mL, and serum
IGF-I ± SD 101.0 ± 39.5 nmol/L, 9.6 ± 5.2 SDS), judged cured
with the previous criteria, were hence reevaluated after a
mean follow-up period of 17.2 ± 8.4 years (range: 3–35 yrs.)
using the recommended standardization for GH and IGF-I
assays.
Hormonal and clinical characteristics of 16 out of 40
patients were previously described [11]. At diagnosis, a pitu-
itary microadenoma was documented in 15 patients and 25
patients had a macroadenoma, with an extrasellar extension
in 20. Patients treated with neurosurgery alone represented
the majority of our series (75%) at long-term follow-up,
whereas in 10 cases surgery was followed by radiotherapy
when appropriate (6 by conventional fractionated radiother-
apy and 4 by Gamma Knife). Sixteen of 40 patients showed
isolated or multiple pituitary failures that were adequately
substituted (10: hypoadrenalism, 2: hypothyroidism, and 8:
hypogonadism). Pregnant womenwere excluded and women
of fertile age were tested during the early follicular phase
of the menstrual cycle (days 1–5); no woman received oral
estrogens.
Clinical and hormonal data of patients are summarized
in Table 1.
2.2. Study Protocol. We used medical records to retro-
spectively investigate posttreatment outcomes and hor-
monal, clinical, neuroradiological, and metabolic data for
International Journal of Endocrinology 3
each patient. Acromegalic patients were evaluated in three
different time points: at the time of remission (phase 1), at
the time of the last available assessment with the GH assay
standardized to IS 80/505 (mean 6.9 ± 5.4 years, phase 2),
and at the last follow-up visit assessed with the GH assay
standardized to IS 98/574 and IGF-I assay standardized to
IS 02/254 (mean 17.2 ± 8.4 years after disease remission,
phase 3). All patients were evaluated after an overnight fast;
blood samples were collected after 1 hour of bed rest with
a slow saline infusion for serum GH (mean of at least 3
samples during saline infusion) and IGF-I levels determina-
tion. After 75 g oral glucose load, additional blood samples
for GH measurements were collected at 30, 60, 90, and 120
minutes. Postglucose GH nadir of individual patient was
defined as the lowest GH value at any time during two-hour
OGTT.
All patients were studied for metabolic and cardiovas-
cular comorbidities; in particular, glucose and insulin levels
at baseline and after 120 minutes during 2 h OGTT, insulin
resistance by the homeostatic model assessment [HOMA-
IR = fasting glucose (mmol/liter) × fasting insulin/22.5]
and the quantitative insulin check index QUICKI = 1/[log
FG (mg/dL) + log FI (mU/liter)], glycosylated haemoglobin
(HbA1c), systolic and diastolic blood pressure (SBP and
DBP) measured according to theWorld Health Organization
(WHO) International Society of Hypertension Guidelines,
lipid profile encompassing total cholesterol (TC), high den-
sity lipoprotein cholesterol (HDL), and triglycerides (TG)
were evaluated. Low density lipoprotein cholesterol levels
(LDL) were evaluated by the formula LDLc = TC-HDLc-
TG/5. Patients were considered affected with hypertension
by the presence of systemic blood pressure ≥140mmHg or
diastolic blood pressure ≥90mmHg or use of antihyperten-
sive therapy, while glucose tolerance was defined according to
accepted international criteria. In addition, body mass index
(BMI) and waist circumference (WC) were evaluated.
They were also investigated for clinical symptoms and
signs of disease (e.g., arthralgia, hyperhidrosis, soft tissues
swelling, paraesthesias, headache and asthenia, and the
fourth finger size of left hand by jewellery rings), for pituitary
function and adequacy of replacement therapy. In a day
different from that of OGTT, a GHRH plus arginine test for
the evaluation of GH peak was performed in order to assess
the residual GH secretion (GHRH 1–29; GEREF, Serono:
1 𝜇g/Kg i.v. at 0min.; arginine hydrochloride, 0.5 g/Kg i.v.
over 30min. from 0 to 30min. up to a maximum of 30 g);
however, since the assessment of residual GH secretion was
not a primary objective of the study, the stimulation test was
performed in 22 out of 40 patients (55%), randomly selected
in both groups. Blood samples for GH evaluation were taken
at 0, 15, 30, 45, 60, 90, and 120min. According to the more
recent criteria, GHdeficiency (GHD) has been defined byGH
peak< 11.5 𝜇g/L if BMIwas below 25Kg/m2,<8.0 𝜇g/L if BMI
was between 25 and 30Kg/m2, and <4.2 𝜇g/L if BMI was over
30Kg/m2 [12].
The occurrence of cardio- and cerebrovascular disease
(e.g., cardiomyopathy, valvular disease, angina, acutemyocar-
dial infarction, and stroke), malignancies, and colorectal
disease (e.g., colonic diverticula, dolichocolon, and colonic
polyps) was investigated as well; smoking habits were also
assessed during the follow-up, as a possible confounding
factor.
Serum samples were kept frozen at −20∘C until assayed.
All hormone determinations were performed in the same
local laboratory using the same assays.
In addition, a magnetic resonance imaging (MRI) of
the sellar region before and after gadolinium contrast was
performed in all patients at last follow-up visit and it was
evaluated by the same neuroradiologist, with the aim of
assessing the presence of potential recurrence or regrowth
with respect to the early postoperative imaging (CT or MRI,
where available).
The Local Ethical Committee (Fondazione IRCCS Ca’
Granda, Milan) approved the protocol study and patients
gave their informed written consent to participate in the
study.
2.3. Hormonal Assays. Until 1992, serum GH levels were
measured with radioimmunoassay (RIA) with polyclonal
Lisophase HGH kit (Sclavo, Milan, Italy). The sensitivity of
the method was 0.3mg/L and intra- and interassay coeffi-
cients of variation were both below 10%. The standards were
calibrated to the first World Health Organization Interna-
tional Reference PreparationHGH-MCR (code 66/217). Sub-
sequently and prior to October 2007, a two-site monoclonal
immunofluorometric assay method (AutoDelfia kit, Wallac,
Inc. OY, Turku, Finland) was used. The sensitivity of this
method was 0.01mg/L and intra- and interassay coefficients
of variation were 2% and 1.7%, respectively. After October
2007, GH was assayed with a chemiluminescence method
(Immulite 2000, Siemens Medical Solutions Diagnostics, Los
Angeles, CA) with a detection limit of 0.01mg/L. In both
cases, the standards were calibrated to the first World Health
Organization International Reference Preparation (code
80/505). After the second semester of 2010, the standardswere
calibrated to the WHO International Standard IS 98/574.
Serum IGF-I concentrations were measured by com-
mercial RIA kits starting from 1985. According to the
RIA assay used before 1996 (Incstar, Stillwater, MN), the
removal of binding proteins was obtained by acidification
and subsequent filtration on ODS C18 cartridges. The intra-
and interassay coefficients of variation were 15 and 16%,
respectively. Afterwards and until 2008, IGF-I levels were
assessed by the commercial radioimmunometric assay kit of
Mediagnost (Tu¨bingen, Germany). The separation of IGF-I
from binding proteins was obtained by acidification in IGF-
II excess, and IGF-II cross-reactivity was less than 0.05%.The
intra- and interassay coefficients of variation were 3.2 and
8.9%, respectively. After 2008, IGF-I levels were measured
by a chemiluminescent immunometric assay (Immulite 2000
IGF-I; Siemens Medical Solutions Diagnostics, Los Angeles,
CA), with an intra- and interassay coefficient of variation of
2.9 and 7.4%, respectively. The values were compared with
those from an appropriate age- and sex-adjusted range and
expressed in standard deviation scores (SDS), as recently sug-
gested.
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All other biochemical and hormonal parameters (e.g.,
glucose, insulin, and prolactin) were measured by standard
procedures.
2.4. Statistical Analysis. Results were expressed as mean ±
SD, unless otherwise stated. A paired Student’s t-test was
performed to compare different variables in case of normally
distributed data; non-Gaussian variables were compared
using Wilcoxon-Mann-Whitney test.
Three groups comparisons were carried out by ANOVA
with Bonferroni post hoc test. In case of nonnormal variables,
a nonparametric Kruskal-Wallis test was used. Fisher’s exact
test was used to compare number of patients in 2 × 2
contingency tables. A backward stepwise logistic regression
model was used to analyse the possible role of clinical and
hormonal variables in determining postglucose GH nadir
classification (<0.4 𝜇g/L or ≥0.4 𝜇g/L). 𝑃 > 0.10 was used as
removal criterion.
Values of 𝑃 < 0.05 were considered statistically signifi-
cant.
Analysis was performed by IBM SPSS statistic software,
version 20.0.
3. Results
3.1. Hormonal and Metabolic Data of the Cohort of Acrome-
galic Patients during Long-Term Follow-Up. Mean serum GH
levels in basal condition were 0.9 ± 1.2 𝜇g/L at long-term
follow-up from disease remission (mean 17.2±8.4 yrs., phase
3), without significant reduction compared to phase 1 and
phase 2 (Table 1). At last follow-up visit, IGF-I levels were
below the upper limit of normal range in all patients, with a
significant decrease if compared to early postoperative phase
(−0.28 ± 1.1 versus 0.6 ± 1.9 SDS, 𝑃 = 0.02, Table 1).
At the long-term follow-up visit, mean postglucose GH
nadir was 0.22 ± 0.20 𝜇g/L (range: 0.01–0.99), with a signif-
icant reduction with respect to phase 1 (0.22 ± 0.20 versus
0.39 ± 0.38 𝜇g/L, 𝑃 < 0.05, Table 1). In particular, female
patients and those with macroadenomas demonstrated a
trend towards lower postglucose GH nadir during long-
term follow-up (Table 1). No significant correlations between
mean postglucose GH nadir and IGF-I SDS, sex, age, BMI,
radiotherapy, and tumor dimension were found (data not
shown). Finally, no correlation between the postglucose GH
nadir values and the presence of GH deficiency or other
pituitary failure was detected.
Overall, no significant differences in any of the evaluated
metabolic parameters (i.e., fasting and 120min glycemia, fast-
ing and 120󸀠min insulinemia, total cholesterol, triglycerides,
HDL-cholesterol, HOMA-IR index, QUICKI, BMI, waist
circumference, and systolic and diastolic blood pressure)
were observed at long-term follow-up compared to early
postoperative period (data not shown).
3.2. Comparison of Hormonal, Metabolic, and Comorbidity
Data between Patients with Postglucose GHNadir over (Group
A) and below 0.4 𝜇g/L (Group B) during Long-Term Follow-
Up. Considering the current criteria for curing acromegaly,
postglucose GH nadir levels over the cut-off limit of 0.4 𝜇g/L
were observed in 11 out of the whole cohort of 40 patients
(28%) in the presence of normal IGF-I concentrations (group
A, 8F&3M, mean age 58.0 ± 7.9 yrs., 3 pts. previously irra-
diated), whereas the remaining 29 patients had postglucose
GH nadir levels below 0.4 𝜇g/L (group B, 17F&12M, mean
age 54.3±12.4 yrs., 7 pts. previously irradiated). No statistical
difference in IGF-I SDS levels at diagnosis, phases 1 and 2, was
found between the two groups (Table 2). Conversely, mean
basal GH levels that were evaluated by multiple sampling
as suggested by the recent consensus criteria in case of
discrepant biochemical results showed a tendency to be
higher in group A than in group B, a tendency that reached
the statistical significance at the last follow-up (Table 2).
During the whole follow-up period, the number of patients
of the two groups who showed GH levels greater than safe
value of 2.5 𝜇g/L was comparable (Table 2). However, mean
GH and postglucose GH nadir levels at last follow-up (phase
3) were significantly lower than phase 1 only in patients of
group B (i.e., postglucose GH nadir < 0.4 𝜇g/L, resp., 𝑃 =
0.03 and 𝑃 = 0.002), whereas the decrease did not reach
statistical significance in patients of group A (Figure 1). The
dynamic evaluation of residual GH secretion performed in 22
out of 40 patients (55%), randomly selected in both groups,
showed that the number of patients with GH deficiency was
not significantly different in group A and group B (data not
shown).
No significant differences in the other evaluated param-
eter (sex, age, timing of follow-up, time of postglucose GH
nadir, tumor size, and radiotherapy) were found between the
two groups (Table 2). In addition, no potential recurrences
or regrowth was detected at last follow-up MRI evaluation
in any patients. Finally, both logistic and linear backward
stepwise regression analyses were carried out to evaluate the
impact of the following predictors: gender, age, adenoma
size, BMI, radiotherapy, preoperative IGF-I SDS, preoperative
mean GH, and postglucose GH nadir levels, on long-term
follow-up postglucose GH nadir levels. None of these factors
resulted to be a significant independent predictor of higher
postglucose GH nadir.
Interestingly, as far as metabolic data and comorbidities
of acromegalywere concerned, no differenceswere evidenced
between group A and group B (Table 3). Finally, the number
of patients who smoke-assessed during the follow-up as a
possible confounding factor, symptom score, ring size, and
pituitary function were not significantly different between
group A and group B (data not shown).
4. Discussion
The consensus guidelines updated in 2010 revisited the
remission criteria in acromegalic patients treated with neu-
rosurgery, defining “disease control” as postglucose GHnadir
levels below 0.4 𝜇g/L and IGF-I levels in age-adjusted normal
range, both dosed with ultrasensitive methods [9]. If these
criteria are applied, it is likely that a percentage of patients
who were previously classified as cured might present post-
glucose GH nadir levels not adequately suppressed, with
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Table 2: Comparison of hormonal data between patients with postglucose GH nadir over (group A) and below 0.4mcg/L (group B) during
longitudinal follow-up. Mean ± SD values are shown.
(a)
Parameters Group A Group B
(GH-n ≥ 0.4) (GH-n < 0.4)
𝑛 11 29 —
Sex (F/M) 8/3 17/12 ns
RT (y/n) 3/8 7/22 ns
Yrs. since disease remission 19.8 ± 9.7 15.1 ± 7.5 ns
(b)
Preoperative Phase 1 Phase 2 Phase 3 Preoperative Phase 1 Phase 2 Phase 3
Basal GH
(𝜇g/L) 25.9 ± 23.3 1.3 ± 0.9 1.3 ± 1.0 1.8 ± 1.6
∗ 18.2 ± 19.6 1.0 ± 0.9 0.9 ± 1.5 0.6 ± 0.7◼
Mean basal GH >2.5 𝜇g/L
(y/n) — 2/9 1/10 3/8 — 3/26 2/27 1/28
Postglucose nadir GH
(𝜇g/L) 9.5 ± 6.5 0.76 ± 0.48
∗ 0.48 ± 0.28∗ 0.51 ± 0.11∗ 13.7 ± 13.5 0.30 ± 0.28 0.17 ± 0.15◼ 0.11 ± 0.08◼
Time of postglucose GH
nadir (min) — — — 62.7 ± 36.6 — — — 63.8 ± 31.0
IGF-I
(SDS) 12.0 ± 6.8 0.4 ± 1.7 −0.7 ± 0.9 −0.4 ± 1.0 9.1 ± 4.7 0.6 ± 2.0 −2.8 ± 14.8 0.2 ± 1.7
F/M: female/male; RT: radiotherapy; y/n: yes/no; yrs.: years; GHD: GH deficiency.
Phase 1: at the time of remission.
Phase 2: at the time of the last available assessment with the GH assay standardized to IS 80/505.
Phase 3: after a long-term follow-up with ultrasensitive GH assay standardized to IS 98/574.
∗
𝑃 < 0.05 versus corresponding phase group B.
◼
𝑃 < 0.05 versus phase 1 same group.
potential implications for the management of the follow-up
of these patients.
The present study explored GH secretion, using the latest
International Standards recently recommended (i.e., code
98/574 for GH assay and code 02/254 for IGF-I assay), as
well as hormonal, clinical, neuroradiological, metabolic, and
comorbidities profile in a cohort of 40 acromegalic patients
considered cured on the basis of the previous guidelines, after
a very long-term follow-up period, in order to assess the
impact of the recently proposed criteria for postglucose GH
nadir values to define the postoperative long-term remission
and a treatment as much as possible personalized.
Themain result was that, after amedian long-term follow-
up of 17.2 years from disease remission, no difference was
found in any of the evaluated parameters between patients
with postglucose GH nadir levels over or below 0.4 𝜇g/L,
using ultrasensitive assays.
In particular, in all patients with postglucose GH nadir
over 0.4 𝜇g/L but below 1 𝜇g/L (group A), who were consid-
ered as cured so far on the basis of the previous guidelines,
IGF-I levels persisted in the normal age-adjusted range
throughout the follow-up evaluation.
In addition, patients of group A, representing 28% of
patients of the present series, did not have a higher incidence
of endocrine and metabolic complications or other comor-
bidities in the long-term follow-up. Finally, none of the fac-
tors considered (i.e., gender, age, adenoma size, preoperative
IGF-I SDS, preoperative mean GH levels, and GH nadir after
glucose load and radiotherapy) resulted to be a significant
independent predictor of higher postglucose GH nadir levels
by logistic regression analysis.
Despite the lack of clinical differences between the two
groups, we observed that the profile of the mean GH levels
and postglucose GH nadir was slightly different in the two
groups at last follow-up. In fact, mean GH levels resulted to
be significantly lower in group B than in group A and, in
parallel, there was a progressive reduction of both mean GH
levels and postglucoseGHnadir values only in group B, while
the IGF-I levels have remained broadly stable and overlapping
postoperatively in both groups. In addition, we found that the
incidence ofmeanGH levels above the safe cut-off of 2.5𝜇g/L
was, however, comparable. In this respect, it is tempting to
speculate that, in analogy with the reduction of the GH nadir
values, the cut-off of 2.5 𝜇g/L for mean safe GH should be
revised in the light of the ultrasensitive assays.
It is at present difficult to ascertain whether this decline
in GH levels might represent a sign of normalization of GH
secretion pattern or, instead, of GH deficiency that frequently
occurs in cured acromegalic patients [13, 14]. A possible bias
in the lack of correlation between GHD and postglucose GH
nadir levels might be related to the fact that only one-half of
the patients were tested for GHD with dynamic stimulation
in the present study.
In the attempt to correlate IGF-I concentrations with
GH secretion and to explore the significance of divergent
GH/IGF-I profiles, the role of adjuvant radiotherapy has been
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Figure 1: (a) Mean GH levels in basal condition, evaluated as the mean of at least three consecutive samples, in patients of group A (i.e., GH
nadir ≥ 0.4mcg/L, upper) and group B (i.e., GH nadir < 0.4mcg/L, lower). Patients of group B showed mean GH levels at long-term follow-
up (phase 3) significantly lower than at the time of remission (phase 1), whereas no difference was observed in group A. ∗𝑃 < 0.05 versus
phase 1. Values are expressed as mean ± SEM. (b) Mean GH nadir, defined as the lowest GH value at any time after glucose administration
(2 h-OGTT), in patients of group A (i.e., GH nadir ≥ 0.4mcg/L, upper) and group B (i.e., GH nadir < 0.4mcg/L, lower). Patients of group B
showedmean GH nadir levels atlong-term follow-up (phase 3) and at the time of the last assessment available with the GH assay standardized
to IS 80/505 (phase 2) significantly lower than at the time of remission (phase 1), whereas the decrease did not reach statistical significance in
patients of group A. ∗𝑃 < 0.05 versus phase 1. Values are expressed as mean ± SEM.
investigated as well. It is known that irradiation seemed to
imply a flat GH secretory pattern, with a less pronounced
effect on the normalization of IGF-I; in addition, identical
degrees and rates of GH decline have been observed in
relationship with different doses administered and in the
techniques employed [15, 16]. In our study, radiotherapy
(conventional fractionated radiotherapy and Gamma Knife)
was equally distributed between group A and group B at
the last follow-up visit and we did not observe significant
differences in postglucose GHnadir levels between irradiated
patients and those not treated with radiotherapy. Otherwise,
we found that mean basal GH levels were significantly
decreased at last follow-up versus phase 1 and phase 2 only
in irradiated patients, when the acromegalic patients were
considered all together.
A clinical interpretation of our results could arise from
the awareness of the problem of GH assay variability: as
Bidlingmaier suggested, several problems with GH assays
cannot be solved solely by using a single calibrator for all
assays and probably the need for strictly “method specific
cut-off values,” advocated from most guidelines to improve
reliability, should be object of collaborative efforts [17]. In
this regard, Arafat and his colleagues have shown that using
Immulite 2000 results are about 2.3 times higher than the
dose Nichols and 6 times higher than the Diagnostic System
Laboratories, even when the recalibration has been taken
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Table 3: Comparison ofmetabolic and comorbid data between patients with postglucose GHnadir over (groupA) and below 0.4 𝜇g/L (group
B) at last follow-up.
Parameter Group A Group B 𝑃
(GH-n ≥ 0.4mcg/L) (GH-n < 0.4mcg/L)
𝑛 11 29 —
BMI (Kg/m2) 24.4 ± 4.6 28.6 ± 4.4 ns
Impaired glucose metabolism (y/n) 4/7 13/16 ns
IFG, IGT, DM (n) 1/2/1 0/9/4
Fasting glucose (mg/dL) 85 ± 14 97 ± 20 ns
Glucose at 120󸀠 (mg/dL) 138 ± 57 128 ± 36 ns
HOMA-IR 2.0 ± 1.7 2.1 ± 1.8 ns
Blood hypertension (y/n) 3/8 12/17 ns
SBP (mmHg) 115 ± 15 122 ± 12 ns
DBP (mmHg) 74 ± 11 79 ± 7 ns
Cardio- and/or cerebrovascular disease (y/n) 6/5 10/19
ns
Valvular heart disease 4 4
Acromegalic cardiomyopathy 1 1
Arrhythmias and cardiomyopathy 0 5
Acute myocardial infarction 1 0
Malignancies (y/n) 3/8 2/27
ns
Mammary carcinoma 1 0
Monoclonal gammopathy 2 0
Olfactory meningioma 0 1
Skin melanoma 0 1
Colorectal disease 2/9 7/22
ns
Diverticula 0 3
Dolichocolon 0 1
Hyperplastic polyps 0 2
Adenomatous polyps 2∗ 1∘
IFG: impaired fasting glucose; IGT: impaired glucose tolerance; DM: diabetes mellitus; NS: not significant.
∗Low grade adenomatous tubular polyps, ∘serrated adenoma with low grade dysplasia.
into account, and have identified a cut-off assay-specific
GH nadir equal to 1mcg/L, able to identify the 78–80%
of patients in remission and 95% of patients with active
disease [6]. Furthermore, a recent publication of Mu¨ller and
colleagues has confirmed that the Immulite GH assay, even
after Siemens claimed to have recalibrated the assay against
the new recombinant standard (i.e., 98/574), still gives GH
concentrations considerably higher than those obtained by all
other assays [18].
Secondly, the present findings seem to corroborate some
previous studies showing that, in presence of discrepant
results, IGF-I may have greater prediction power over post-
glucose GH nadir values [2, 11, 19], even though some limita-
tions of IGF-I parameter cannot be neglected, such as binding
proteins interference and inadequate international reference
standards and reference values [20]. In the past, subtle
abnormalities of GH suppression in patients with normal
IGF-I values have been extensively investigated. In particular,
it has been suggested that incomplete GH suppression during
OGTT might indicate persistence of postoperative central
deregulation and not necessarily GH hypersecretion, while
IGF-I levels might remain normal even in the presence of
mild GH excess [19, 21]. In a previous work, we demonstrated
that defective GH suppression to glucose is unlikely to be
due to functional and/or anatomical hypothalamic-pituitary
disconnection, since a normal postglucose GH nadir was
recorded in patients with various hypothalamic-pituitary
disorders other than acromegaly [22].
The relatively low number of subjects evaluated in our
study and the variability of factors that may influence GH
levels require a degree of caution in reaching final conclusion,
even though the use of the same central well-validated GH
and IGF-I assays in all patients represents a strength that
enables a confident reading of our main findings. Never-
theless, the very long-term follow-up of these acromegalic
patients, considered cured on the basis of the previous
guidelines, seems to demonstrate that they do not need a
closer or more intensive monitoring than patients that met
the current criteria of disease control (e.g., postglucose GH
nadir less than 0.4mcg/L and normal age-adjusted IGF-
levels), suggesting instead that the cut-off of 0.4mcg/L might
be too low for the currently used GH assay. Indeed, according
to the clinical context, a periodical long-term monitoring of
both GH and IGF-I levels is required in acromegalic patients,
in reason of either GH deficiency occurrence or possibly
disease recurrence.
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